Price data is not available
Innate Pharma SA (IPHA) Stock Price, Quote, News & History
IPHANASDAQ
Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.
You can purchase shares of Innate Pharma (NASDAQ:IPHA) through any online brokerage.
Other companies in Innate Pharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Innate Pharma has a consensus price target of $6.50.
The stock price for Innate Pharma (NASDAQ: IPHA) is $1.46 last updated November 5, 2026 at 6:28 AM EST.
There are no upcoming dividends for Innate Pharma.
Innate Pharma does not have any upcoming earnings scheduled.
There is no upcoming split for Innate Pharma.
Innate Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through...
